Robotic vs. Laparoscopic vs. Open Living Donor Hepatectomy (NCT06062706) | Clinical Trial Compass
UnknownNot Applicable
Robotic vs. Laparoscopic vs. Open Living Donor Hepatectomy
Saudi Arabia3,448 participantsStarted 2023-08-06
Plain-language summary
This will be a study to examine the outcomes of open, laparoscopic, and robotic Living Donor Liver Transplantation (LDLT) procedures. The analysis will encompass 3,448 cases (1,724 donor-recipient pairs) from January 2011 to March 2023, documenting the transition between these surgical techniques, with a noted crossover in 2018.
Who can participate
Age range
1 Month – 75 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* All donor and recipient pairs that underwent LDLT at the study institution
* Between 01 January 2011 to 31 March 2023
* Both adult-to-adult and adult-to-pediatric LDLT are included.
Exclusion Criteria:
* Dual and domino LDLT are excluded.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Donor overall morbidity rate
Timeframe: From date of donor hepatectomy until the date of first hospital discharge assessed up to 90 days postoperatively.
2
Recipient overall morbidity rate
Timeframe: From date of liver transplantation until the date of hospital discharge assessed up to 90 days postoperatively.
3
Recipient in-hospital mortality rate
Timeframe: From date of liver transplantation until the date of death assessed up to 90 days post-transplant.
Trial details
NCT IDNCT06062706
SponsorKing Faisal Specialist Hospital & Research Center